The average of price targets set by Wall Street analysts indicates a potential upside of 171.4% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable ...
BIO (ETNB) is looking like an interesting pick from a technical perspective, as the company reached a key level of support.
UBS raised the firm’s price target on 89bio (ETNB) to $38 from $25 and keeps a Buy rating on the shares. Akero Therapeutics (AKRO) reported ...
89bio's pegozafermin, an FGF21 analog, is currently being evaluated in three Phase III trials. Two of these trials are focused on different MASH populations, while the third targets SHTG patients.
89bio announced a public offering of 21.67 million shares at $8.75 each, aiming for $250 million in gross proceeds. The company's reliance on an upsized public offering may indicate a need for ...
89bio, Inc. has announced the launch of an underwritten public offering for $250 million in common stock, with the option for some investors to purchase pre-funded warrants instead. The company ...
89bio (NASDAQ: ETNB) couldn't quite keep pace with the broader stock market on Tuesday. Investors were hesitant to buy shares of the clinical-stage biotech, following news that it was floating a ...
89bio's main value driver is Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. Management mentioned we should get its SHTG topline data by 2H2025. This could be a ...
89bio, Inc. (NASDAQ:ETNB – Free Report) – Research analysts at Leerink Partnrs issued their FY2029 EPS estimates for shares of 89bio in a research note issued on Sunday, February 2nd.
SAN FRANCISCO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative ...
89bio, Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver ...